Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Merck
Colorcon
Mallinckrodt

Last Updated: May 28, 2022

Investigational Drug Information for GKT137831


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug GKT137831?

GKT137831 is an investigational drug.

There have been 5 clinical trials for GKT137831. The most recent clinical trial was a Phase 2 trial, which was initiated on June 26th 2017.

The most common disease conditions in clinical trials are Idiopathic Interstitial Pneumonias, Albuminuria, and Fibrosis. The leading clinical trial sponsors are Genkyotex SA, Genkyotex Innovation SAS, and Eurofins Optimed.

There are nine US patents protecting this investigational drug and seventy-eight international patents.

Recent Clinical Trials for GKT137831
TitleSponsorPhase
GKT137831 in IPF Patients With Idiopathic Pulmonary FibrosisUniversity of Alabama at BirminghamPhase 2
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female SubjectsGenkyotex SAPhase 1
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in TabletsEurofins OptimedPhase 1

See all GKT137831 clinical trials

Clinical Trial Summary for GKT137831

Top disease conditions for GKT137831
Top clinical trial sponsors for GKT137831

See all GKT137831 clinical trials

US Patents for GKT137831

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GKT137831 See Plans and Pricing Selective Nox-1 inhibitor peptides and uses thereof Universite de Bordeaux (FR) INSERM (FR) See Plans and Pricing
GKT137831 See Plans and Pricing Skin enhancing compositions and methods Sytheon Limited (Boonton, NJ) See Plans and Pricing
GKT137831 See Plans and Pricing Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (Plan-Les-Ouates, CH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Merck
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.